参考文献/References:
[1] Sunthornthepvarakul T,Angkeow P,Weiss RE,et al.An identical missense mutation in the albumin gene results in familial dysalbuminemic hyperthyroxinemia in 8 unrelated families[J].Biochem Biophys Res Commun,1994,202(2):781-787.DOI:10.1006/bbrc.1994.1998.
[2] Vaccarella S,Dal Maso L,Laversanne M,et al.The impact of diagnostic changes on the rise in thyroid cancer incidence:a population-based study in selected high-resource countries[J].Thyroid,2015,25(10):1127-1136.DOI:10.1089/thy.2015.0116.
[3] 中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华内分泌代谢杂志,2012,28(10):779-797.DOI:10.3760/cma.j.issn.1000-6699.2012.10.002.
[4] Carayon P,Thomas-Morvan C,Castanas E,et al.Human thyroid cancer:membrane thyrotropin binding and adenylate cyclase activity[J].J Clin Endocr and Metab,1980,51(4):915-920.DOI:10.1210/jcem-51-4-915.
[5] Grani G,Ramundo V,Verrienti A,et al.Thyroid hormone therapy in differentiated thyroid cancer[J].Endocrine,2019,66(1):43-50.DOI:10.1007/s12020-019-02051-3.
[6] Haugen BR,Alexander EK,Bible KC,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(1):1-133.DOI:10.1089/thy.2015.0020.
[7] Jonklaas J,Sarlis NJ,Litofsky D,et al.Outcomes of patients with differentiated thyroid carcinoma following initial therapy[J].Thyroid,2006,16(12):1229-1242.DOI:10.1089/thy.2006.16.1229.
[8] Cooper DS,Specker B,Ho M,et al.Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer:results from the national thyroid cancer treatment cooperative registry[J].Thyroid,1998,8(9):737-744.DOI:10.1089/thy.1998.8.737.
[9] 王薇.分化型甲状腺癌术后促甲状腺素抑制治疗的艺术[J].药品评价,2015(9):7-10,39.DOI:10.3969/j.issn.1672-2809.2015.09.002.
[10] 王坤玲,何向辉,张桂芝,等.家族性异常白蛋白血症性高甲状腺素血症合并甲状腺癌一例报道及文献复习[J].中华内分泌代谢杂志,2018,34(7):602-604.DOI:10.3760/cma.j.issn.1000-6699.2018.07.014.
[11] Petersen CE,Ha CE,Jameson DM,et al.Mutations in a specific human serum albumin thyroxine binding site define the structural basis of familial dysalbuminemic hyperthyroxinemia[J].J Biol Chem,1996,271(32):19110-19117.DOI:10.1074/jbc.271.32.19110.
[12] Wiersinga WM.T4+T3 combination therapy:any progress?[J]Endocrine,2019,66(1):70-78.DOI:10.1007/s12020-019-02052-2.
[13] Jonklaas J,Bianco AC,Cappola AR,et al.Evidence-Based use of levothyroxine/liothyronine combinations in treating hypothyroidism:a consensus document[J].Thyroid,2021,31(2):156-182.DOI:10.1089/thy.2020.0720.
[14] Mendel CM,Weisiger RA,Jones AL,et al.Thyroid hormone-binding proteins in plasma facilitate uniform distribution of thyroxine within tissues:a perfused rat liver study[J].Endocrinology,1987,120(5):1742-1749.DOI:10.1210/endo-120-5-1742.
[15] Mimoto MS,Refetoff S.Clinical recognition and evaluation of patients with inherited serum thyroid hormone-binding protein mutations[J].J Endocrinol Invest,2020,43(1):31-41.DOI:10.1007/s40618-019-01084-9.
[16] Abali S,Yavas Abali Z,Yararbas K,et al.Rapid molecular diagnosis of ALB gene variants prevents unnecessary interventions in familial dysalbuminemic hyperthyroxinemia[J].J Pediatr Endocrinol Metab,2021,34(9):1201-1205.DOI:10.1515/jpem-2021-0087.
[17] Kragh-Hansen U,Galliano M,Minchiotti L.Clinical,genetic,and protein structural aspects of familial dysalbuminemic hyperthyroxinemia and hypertriiodothyroninemia[J].Front Endocrinol,2017,8:297.DOI:10.3389/fendo.2017.00297.
[18] Richardson SJ,Wijayagunaratne RC,D'Souza DG,et al.Transport of thyroid hormones via the choroid plexus into the brain:the roles of transthyretin and thyroid hormone transmembrane transporters[J].Front Neurosci,2015,9:66.DOI:10.3389/fnins.2015.00066.
[19] Bernal J,Guadaño-Ferraz A,Morte B.Thyroid hormone transporters-functions and clinical implications[J].Nat Rev Endocrinol,2015,11(12):690.DOI:10.1038/nrendo.2015.186.